Design and in Silico Construction of New Efficient Antibodies Against Gastric Tumor-associated Antigens Towards Introducing Combined Strategy for Vaccine Tumor Therapy

Authors

  • Ghazaleh Ghavami Drug Design and Bioinformatics Unit, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
  • Sakineh Shahidi Drug Design and Bioinformatics Unit, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
  • Sholeh Maslehat Drug Design and Bioinformatics Unit, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
  • Soroush Sardari Drug Design and Bioinformatics Unit, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
  • Zohreh Mazinani Drug Design and Bioinformatics Unit, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Abstract:

Introduction: Gastric cancer, as the second reason of cancer mortality around the world, is defined as one of the serious health problems and a wide range of current research is focused to overcome the challenges relevant to its successful therapy. Employing recent approaches in the field of vaccine tumor therapy and immunotherapic strategies such as utilization of monoclonal antibodies can play significant roles in achieving efficient therapeutic means to combat the disease. Methods and Results: In this study, computational methods including three-dimensional modeling, based on sequence combinational pattern identification together with docking procedures have been employed for design and in silico construction of prolific and effective antibody structures against HER-2 and MAGE-3 antigens. These methods led to introduction of novel and efficient anti-HER2 and anti-MAGE3 antibodies. For instance, combinational pattern of bH1 antibody (light chain) and IGG1-KAPPA 4D5 antibody (heavy chain) which obtained an exceptional score of 844.83 KJ/mol as the new candidate for cancer vaccine therapy, whereas Herceptin scored 453.4 KJ/mol. In addition, the suggested pattern for designing antibody against MAGE-3 with combination of bH1 antibody (heavy chain) and HLA-A 0201 (light chain) achieved acceptable score of 640.8 KJ/mol.  Conclusion: It is envisaged that the results obtained from the current research could be utilized to develop efficient combined strategies for vaccine therapy of gastric cancer.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

design and in silico construction of new efficient antibodies against gastric tumor-associated antigens towards introducing combined strategy for vaccine tumor therapy

introduction: gastric cancer, as the second reason of cancer mortality around the world, is defined as one of the serious health problems and a wide range of current research is focused to overcome the challenges relevant to its successful therapy. employing recent approaches in the field of vaccine tumor therapy and immunotherapic strategies such as utilization of monoclonal antibodies can pla...

full text

Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens.

Novel treatment strategies for cancer that are based on a more detailed understanding over the tumor biology are based on the latest new technology and are expected to improve the current treatment outcome for patients with cancer. However, many of these strategies still have one common and critical problem, being their limited specificity for tumor cells. In this context, antibodies against tu...

full text

Human monoclonal antibodies directed against melanoma tumor-associated antigens.

To analyze the humoral immune response to melanoma, human-mouse hybridomas were generated by the fusions of regional lymph node lymphocytes of patients with the mouse myeloma cell line M5. Six stable hybridomas were cloned from six separate lymphocyte parents obtained from three patients. Ascites were obtained from nude mice after i.p. injection with cultured hybridoma cells. The monoclonal ant...

full text

Therapeutic Antibodies against Intracellular Tumor Antigens

Monoclonal antibodies are among the most clinically effective drugs used to treat cancer. However, their target repertoire is limited as there are relatively few tumor-specific or tumor-associated cell surface or soluble antigens. Intracellular molecules represent nearly half of the human proteome and provide an untapped reservoir of potential therapeutic targets. Antibodies have been developed...

full text

Approaching untargetable tumor-associated antigens with antibodies

Approved therapeutic antineoplastic antibodies have targeted extracellular or cell-surface molecules. ESK1 is the first fully human T-cell receptor-like antibody targeting an intracellular tumor-associated antigen, Wilm's tumor 1 (WT1). In murine xenograft models, ESK1 exhibits a high specificity and exert robust antineoplastic effects against human cancers that express WT1 epitopes on HLA-A201...

full text

Tumor Associated Carbohydrate Antigens in Targeted Therapy

Tumor associated carbohydrate antigens (TACAs) are a class of glycans with important structural and signaling functions playing a major role in cell proliferation, differentiation, and apoptosis relevant to oncology. Tumor cells expressing TACAs influence prognosis and survival of cancer patients. Careful consideration must be given to structural aspects during rational design of small molecule...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 1  issue 2

pages  7- 11

publication date 2014-11

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023